Shaanxi Micot Pharmaceutical Technology's (HKG:2335) phase II clinical trial of MT200605 for the treatment of AIS obtained top-line results, according to a Monday Hong Kong bourse filing.
Shares of the company were nearly 3% in Tuesday afternoon trading.
Results showed that the study reached its primary endpoint with statistically significant and clinically meaningful outcomes, with the drug showing a favorable efficacy trend and safety and tolerability profile.